Wockhardt Bio AG, a subsidiary of Wockhardt Limited, has incorporated three new wholly-owned step-down subsidiaries: Wockhardt Swiss AG (Switzerland), Wockhardt Suisse USA Holding Corporation (USA), and Wockhardt Suisse USA LLC (USA). This strategic move aims to bolster the company’s global operations and market presence. These entities are established to support Wockhardt’s pharmaceutical business.
New Subsidiaries Incorporated
Wockhardt Limited has announced the incorporation of three new step-down subsidiaries, a move intended to strengthen its international footprint and support future growth initiatives. These new entities are 100% owned by Wockhardt Bio AG.
Details of the New Entities
The newly incorporated subsidiaries are:
- Wockhardt Swiss AG (Switzerland): A wholly-owned subsidiary based in Zug, Switzerland. Capital amounts to CHF 100,000 divided into 100,000 shares.
- Wockhardt Suisse USA Holding Corporation (USA): Based in Delaware, USA, with a capital of USD 50,000 divided into 1,000 shares.
- Wockhardt Suisse USA LLC (USA): Also based in Delaware, USA, with a capital of USD 50,000 divided into 1,000 shares.
Strategic Intent
These incorporations will help Wockhardt streamline and expand its operations, particularly in the areas of antibiotic and other pharmaceutical products across the United States. They align with the company’s main business objectives and set the stage for potential future expansion in key markets.
Operational Status
As of December 16, 2025, none of the newly incorporated entities have commenced business operations. All three are intended to support Wockhardt’s core pharmaceutical business.
Source: BSE
